Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086723 · ClinicalTrials.gov registry record · Phase 1
In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00086723: Completed Phase 1 study, sponsored by Northwestern University.
NCT00086723 is a Phase 1 study that has completed, run by Northwestern University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086723, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Tissue plasminogen activator and captopril may help the body generate angiostatin. Angiostatin may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of tissue plasminogen activator and captopril and to see how well they work in treating patients with progressive metastatic cancer.
Interventions
- BIOLOGICAL recombinant tissue plasminogen activator
- DRUG captopril
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
What the finished NCT00086723 record still lists
NCT00086723 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which recombinant tissue plasminogen activator is the first listed.
NCT00086723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00086723 about?
NCT00086723 is a clinical study titled "In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer". RATIONALE: Tissue plasminogen activator and captopril may help the body generate angiostatin. Angiostatin may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of tissue plasminogen activator and captopril and to...
What is the current status of trial NCT00086723?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-07. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00086723?
The interventions under investigation include: recombinant tissue plasminogen activator (BIOLOGICAL), captopril (DRUG).
Who is sponsoring clinical trial NCT00086723?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia